Skip to main content
COAG logo

COAG · Hemab Therapeutics Holdings, Inc. · Financials

Track COAG — free
$38.71 -0.45 (-1.14%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.83B
Shares
46.73M
Volume · Nov 19 43.99K Avg daily vol (3M) 496.12K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Chart any reported metric, KPI or segment over time — the full statement history lives here

No structured figures reported for this view yet.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-09-30 USD 462,000 10-Q filed 2026-11-10
Noncurrent operating lease liabilities 2026-09-30 USD 503,000 10-Q filed 2026-11-10
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 8.00×
EV/EBIT
—
Peer median 21.06×
P/E (TTM)
—
Peer median 17.61×
Price/Sales (TTM)
—
Peer median 9.39×
Price/Book
4.26×
Peer median 3.18×

Peer medians compare against the 270 similar-size Biotechnology companies (of 593 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 2114044 CUSIP 423494103 13F (30d) 89 filings 88 filers Visit website Investor relations